Develops small-molecule drugs that direct the body to break down disease-related proteins, for patients with immune-mediated diseases, inflammatory conditions and cancer.
10-K for FY2025, filed Mar 17, 2026
Pharmaceutical partners pay upfront to license programs and support research; further payments may follow when development milestones are met, with royalties on licensed-product sales. The company also earns collaboration revenue as it conducts research over time and when a license is transferred.
10-K for FY2025, filed Mar 17, 2026In October 2023, our wholly-owned subsidiary, Monte Rosa Therapeutics AG, or Monte Rosa AG, entered into a strategic collaboration and…View ↗
Under the agreement, the Company received a $120.0 million non-refundable upfront payment from Novartis. The Company is entitled to receive…View ↗
Revenue is recognized based on the amount of the transaction price that is allocated to each respective performance obligation when or as…View ↗
F-12 performance in transferring control of the associated goods and/or services to the customer. The Company uses input methods to measure…View ↗
$123.7M
10-K for FY2025, filed Mar 17, 2026
$123.7M ↗
Pharmaceutical companies collaborate directly with Monte Rosa: Roche selects oncology and neuroscience targets for discovery work, while Novartis licenses programs in immunology and inflammation.
10-K for FY2025, filed Mar 17, 2026
Licensing programs
The company has moved from retaining worldwide rights to its pipeline to licensing selected programs to pharmaceutical partners, which take on later development and commercialization.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 17, 2026We have leveraged our QuEEN™ platform to generate our pipeline of product candidates with the potential to treat a diverse range of…View ↗
Cancer focus
The newer description centers the lead cancer program on metastatic castration-resistant prostate cancer; the earlier report covered several MYC-driven tumor types, including lung and neuroendocrine cancers.
10-K for FY2022, filed Mar 16, 2023 10-K for FY2025, filed Mar 17, 2026Our most advanced product candidate, MRT-2359, is an orally bioavailable MGD targeting the translation termination factor protein GSPT1.…View ↗
MRT-2359 is an orally bioavailable MGD targeting the translation termination factor protein GSPT1 and is currently in clinical development…View ↗
Competes with C4 Therapeutics, Nurix Therapeutics, Kymera Therapeutics, Bristol-Myers Squibb, Novartis, AstraZeneca, Roche, Novo Nordisk, Ventyx Biosciences, BioAge Labs, NodThera, Pfizer, Merck, BeOne Medicines, and Incyte
10-K for FY2025, filed Mar 17, 2026The main competitors in our efforts to develop targeted protein degraders or MGD therapeutics for patients include, but are not limited to…View ↗
Loading...